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Abstract 
Thalassemia is a multisystemic disease in the field of hemolysis and chronic anemia caused by the erythropoietic disorder. 
The severe effects of iron overload from continuous blood transfusion iron chelators side effects, and involvement of 
multiple organs in thalassemias such as heart failure, liver, and endocrine dysfunction can all affect kidney function. 
Although there has been much debate about changes in renal function in thalassemia for many years, the presence of 
hyperfiltration and ultimately, decreased renal function in almost all studies. It seems for the researchers to look beyond 
kidney function in a thalassemia perspective, because of secretory biomarkers of proximal tubular renal cells that are 
sensitive to pathologic agents, which may be a good indicator of the courses of treatment and prognosis of patients. Future 
studies will be sooner or later. 
Keywords: Thalassemia, Renal complications, Iron overload. 
*
Corresponding Author: Malihe Najafpour; Email: malihe_najafpour@modares.ac.ir 
Please cite this article as: Malaki M, Najafpour M, Talebi M, Azimi A. Change in Attitude in Renal Function in 
Major Beta Thalassemia. Arch Med Lab Sci. 2020;6:1-5 (e24). https://doi.org/10.22037/amls.v6.33057 
 
Introduction 
Thalassemia is a type of chronic, microcytic, and 
inherited anemia that is associated with defects in 
hemoglobin synthesis and the reduction in the life 
span of red blood cells (1). Beta thalassemia is more 
common than alpha-thalassemia (2). Although the 
quality of life for patients with beta-thalassemia has 
improved in recent years, complications are still a 
great challenge in these patients (2, 3). 
Cause of renal complications in thalassemia 
For the first time, renal dysfunction has reported in 
patients with beta-thalassemia major (βTM) (4). 
Nowadays, renal complications have been seen at 
an earlier age and researchers have considered early 
detection as an important issue (5). Three 
mechanisms are involved in the pathomechanism of 
renal complications in patients with βTM: chronic 
anemia, iron overload, and specific iron chelators 
(6). Chronic anemia and hypoxia lead to impaired 
renal tubular function by oxidative stress and lipid 
peroxidation (6, 7). Red blood cell hemolysis due to 
hypoxia is also effective in this process (8). Chronic 
anemia reduces vessel resistance and increased 
renal plasma flow and GFR (7, 8). Increased GFR 
eventually leads to increased matrix volume and 
cellularity, and these events lead to the onset of 
sclerosis. For a long time, stretching of the 
glomerular capillary wall followed by endothelial 
and epithelial injury cause to decrease in GFR and 
progressive kidney damage (6, 7). 
Iron overload is a side effect of blood transfusion in 
βTM that leads to multi-organ dysfunction in the 
heart, liver, kidney, and endocrine system (9). It 
seems that iron deposition in renal tubes is the main 
cause of tubular damage. Iron overload can induce 
lipid peroxidation and produce free radical oxygen 
in kidney tubular cells and leads to cell damage 
(10). Damaged tubular cells secrete growth factors 
and cytokines, leading to tubule-interstitial fibrosis 
and glomerular sclerosis. Excess iron as a result of 
repeated transfusions in the form of hemosiderin 
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falls into the nephrons and deposition of 
hemosiderin in the paroxysmal and distal tubes 
leads to tubular necrosis in these patients (6). 
Iron chelator drugs are another mechanism involved 
in renal dysfunction in the context of βTM. 
Evidence points to glomerular and tubular 
nephrotoxicity followed by usage of some drug (11, 
12). The possible mechanism may be due to 
mitochondrial dysfunction and uninterrupted 
production of adenosine and adenosine triphosphate 
(13). All causes have been shown in figure 1. 
 
 
Figure 1. Cause of kidney damage in patients with 
major beta-thalassemia 
 
Review of renal disease in thalassemia 
The main focus of studies on kidney evaluation is 
on glomerular and tubular (proximal or distal) 
function. GFR is an important parameter for 
glomerular evaluation. Some studies have shown an 
increase in GFR whereas others have reported its 
decrease (14-16). In Lai ME et al. (8) study beta-
thalassemia major patients had normal GFR during 
the ten years follow-up. This result has been in 
contrast to the study performed in Tabriz(16). They 
have found an elevation in GFR level 
(hyperfiltration) which indicates glomerular 
dysfunction. Since hyperfiltration has related to age, 
another study has evaluated a wider range of ages 
and the mean of GFR was higher (134 ± 35 
mL/min/1.73 m² vs 154±66 mL/min/1.73 m²) (15). 
Basma et al. (17) study on β-thalassemia major, also 
has shown that a significant percentage of patients 
have had glomerular dysfunction.  
Usually, creatinine and albumin have used to 
evaluate tubular function. One study in Egypt has 
shown an increase in creatinine and a decrease in 
clearance of creatinine and GFR (17). In contrast, in 
some studies, creatinine, and clearance of creatinine 
have been in the normal range (15, 16, 18, 19). 
Since studies on creatinine and its clearance have 
shown different results, it is better to check early 
markers of renal dysfunction such as serum 
cystatin C, which is independent of age, sex, and 
muscle mass (20). The increase in cystatin C has 
been observed in previous studies that point to 
glomerular damage (14, 20). Alpha-1 microglobulin 
and retinol-binding protein (RBP) have been among 
new markers in examining the proximal tubular 
function and acute kidney injury (6). Tantawy et al. 
study has shown that 54.8% of patients with 
thalassemia have increased urinary excretion of 
alpha-1 microglobulin and 69.4% of them have 
increased urinary RBP levels. Alpha-1 
microglobulin level has a positive correlation with 
serum ferritin and history of splenectomy in 
patients with thalassemia patients. RBP has had a 
negative correlation with creatinine and a positive 
correlation with ferritin and urinary total protein 
(21). 
Proximal tubular damage has been associated with 
increases in low molecular weight protein in urine 
until tubular cell necrosis. It has been a common 
finding in thalassemia (22, 23). Almost all studies 
have been shown elevation in low molecular weight 
protein. The N-acetyl β-di glucose amine (NAG), β2 
microglobulin, calcium, phosphate, magnesium, and 
uric acid excretion also have been seen in a 
significant percentage of patients (22). In Sadeghi-
Bojd et al. (9) study patients with βTM have had 
renal damage, such as hypercalciuria, proteinuria, 
glycosuria, magnesiumuria. They didn’t measure 
GFR in their study that depends on factors like 
height, age, weight, race, and sex variables. Studies 
in sickle cell/beta-thalassemia (24) have shown an 
increase in cystatin C, NAG, and β2 macroglobulin. 
Cystatin C and β2 macroglobulin have a strong 
correlation with a clearance of creatinine and age. 
NAG has shown a correlation with proteinuria. 
Serum cystatin C and β2 microglobulin level, 
proteinuria, and calciuria have been increased in 
Dimitriadou M et al. (14) study in βTM. The 
proteinuria has been also reported by the East 
Azerbaijan study (15). Harris et al. (25) reported 
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low blood pressure and proteinuria as a possible 
reason for the presence of interstitial renal tract 
disease. Prolonged hyperfiltration can cause 
proteinuria in patients with thalassemia. 
Ca/vitamin D consumption in most patients with 
thalassemia could lead to kidney stones and tubular 
damage (23). Tubulopathy with an increase in uric 
acid, phosphor, and urinary albumin, Ca, phosphor 
and uric acid have been reported in two studies (3, 
9).  
A study in 2015 has been shown new urinary 
markers in proximal tubular damage diagnosis such 
as NGAL (neutrophils gelatinase-associated 
lipocalin), KIM (kidney injury molecule), L-FABP 
(liver-type acid-binding protein). They have 
calculated the ratio of these parameters to creatinine 
in random urine, NGAL has shown an increase in 
beta-thalassemia compared with the normal group 
but there has been no correlation between urinary 
KIM and L-FABP to creatinine ratio between 
thalassemia patients and healthy controls (26).  
Hypercalciuria, hyperuricosuria, hypophosphaturia, 
proteinuria, and changes in GFR have been some 
tubular and glomerular complications in major 
thalassemia. 
Review of genetic factors in renal complications 
Although there has been much debating about 
changes in renal function in thalassemia for many 
years, it's time to research the effects of genetic 
factors on the development of renal dysfunction in 
this group of patients (27). Researchers focus on 
Vitamin D receptor (VDR) polymorphism(shown in 
figure 2) because the kidney is one of the VDR 
target organs (28).  
 
 
Figure 2. Vitamin D gene polymorphisms on chromosome 
 
Dimitriadue et al. (14) have shown that patients 
homozygous for f allele (ff) in VDR, had increasing 
levels of cystatin C whereas, in Najafpour et al. (29) 
study, no significant correlation between renal 
dysfunction and FOK-I polymorphism have 
observed in VDR. Because studies about this matter 
as limited, more studies are needed to decide about 
the role of genetic factors in renal complications. 
Review of drug complications 
Iron chelator's side effects are important factors that 
show correlations with kidney disease. Pump 
dysfunction after treatment with deferoxamine (10), 
increased levels of creatinine and beta-
microglobulin in deferazirox (30), glomerular and 
tubular dysfunction, and oxidative stress in 
deferoxamine (5) have been some of the drug side 
effects in thalassemia. A cohort study in patients 
under the treatment with deferazirox(with dosage: 
20mg/kg/day) has shown tubular nephropathy with 
an increase in creatinine, β2 macroglobulin, and 
magnesium, and decrease in GFR, potassium, 
calcium (12). A combination of deferazirox and 
silymarin (a herbal antioxidant), did not affect renal 
function, but the use of each drug lonely has been 
shown to decrease oxidative stress. They suggest 
that the co-interaction between two drugs, maybe 
the cause of this difference (31). Renal tubular 
dysfunction in patients with consumption of 
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deferazirox have suggested that it’s better to check 
up renal function for prevention the renal 
involvement (32). Hypercalciuria during the 
consumption of deferasirox has been as another 
finding (15). 
Conclusion 
In conclusion, the renal complication is one of the 
major complications in patients with major beta-
thalassemia. According to findings, we can detect 
early renal dysfunction with an evaluation of 
glomerular and tubular specific markers spatially 
genetic markers and prevent renal injury by 
monitoring the patients after the treatment with iron 
chelator drugs. So change of attitude to the role of 
genetic factors in renal failure in thalassemia can 
increase the quality of life in this group of patients. 
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